---
layout: post
title: "Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics"
date: 2026-02-05 19:09:39 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-09136
original_published: 2020-04-30 00:00:00 +0000
significance: 8.00
---

# Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** April 30, 2020 00:00 UTC
**Document Number:** 2020-09136

## Summary

The National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) hereby announces updates to the Best Pharmaceuticals for Children Act (BPCA) Program priorities for 2020-2021. The Best Pharmaceuticals for Children Act (BPCA) seeks to improve the level of information on the safe and effective use of pharmaceuticals used to treat children. The BPCA requires that the NIH identify the drugs of highest priority for study in pediatric populations, publish a list of drugs/needs in pediatric therapeutics, and fund studies in the prioritized areas. This notice will provide a brief update on the current progress of the BPCA Program and provide the current Priority List of Needs in Pediatric Therapeutics.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/04/30/2020-09136/best-pharmaceuticals-for-children-act-bpca-priority-list-of-needs-in-pediatric-therapeutics)
- API: https://www.federalregister.gov/api/v1/documents/2020-09136

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
